Targeted therapies and surgical issues in gastrointestinal cancers

Targeted Oncology

Volumn 3, Issue 2, 2008, Pages 119-125

  Parikh, Alexander A ^a   Ellis, Lee M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Bevacizumab; Cetuximab; Complications; Epidermal growth factor; Panitumumab; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

EID: 42449148230     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0075-8     Document Type: Article

References (46)

1. Gordon MS et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843-850
2. Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39(7-8):1349-1357
3. Bevacizumab Package Insert, Genentech Biooncology Inc
4. Scappaticci FA et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173-180
5. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23(22):4853-4855
6. D'Angelica M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14(2):759-765
7. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas AM, Curley SA, Feig BW (2007) Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. 2007 Gastrointestinal Cancers Symposium
8. Reddy SK et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206(1):96-106
9. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
10. Giantonio BJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544
11. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860-1869
12. Badgwell BD et al (2007) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. DOI 10.1093/annonc/mdm508
13. Kretzschmar A, Cunningham D, Berry S (2006) Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumor resection: preliminary results from the First BEATrial. 2006 American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Abstract 248
14. Sugrue M, Kozloff M, Hainsworth J (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. 2006 American Society of Clinical Oncology Annual Meeting, Abstract 3535
15. Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25(20):2902-2908
16. Buchs NC et al (2008) Incidence, consequences, and risk factors for anastomotic dehiscence after colorectal surgery: a prospective monocentric study. Int J Colorectal Dis 23(3):265-270
17. Kabbinavar FF et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697-3705
18. Benoist S et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92(9):1155-1160
19. Muratore A et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14(2):766-770
20. Scoggins CR et al (1999) Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 6(7):651-657
21. Assy N et al (1999) Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 30(5):911-915
22. Furnus CC et al (2003) Chronobiology of the proliferative events related to angiogenesis in mice liver regeneration after partial hepatectomy. Cell Biol Int 27(4):383-386
23. Kraizer Y et al (2001) Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Commun 287(1):209-215
24. Aloia T et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24(31):4983-4990
25. Parikh AA et al (2003) Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7(8):1082-1088
26. Vauthey JN et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065-2072
27. Gruenberger T, Tamandi D, Puhalla H, Scheithauer W, Zielinski C, Gruenberger B (2007) Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 25(18S) (2007 ASCO Annual Meeting Proceedings Part I):4064
28. Ribero D et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761-2767
29. Clark JW et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472-5480
30. Moore M et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688-1694
31. Abou-Alfa GK et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293-4300
32. Eng FC et al (2007) Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol DOI 10.1016/j.ejso.2007.09.009
33. Sunitinib Package Insert; Pfizer Oncology
34. Normanno N et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2-16
35. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33(4):369-385
36. Erbitux (Cetuximab) Package Insert; ImClone Systems Inc./Bristol-Myers Squibb Co.
37. Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
38. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Köhne C (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25(18S) (2007 ASCO Annual Meeting Proceedings Part I):4000
39. Venook A et al (2006) Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24(18S) (2006 ASCO Annual Meeting Proceedings Part I):3509
40. Moyer JD et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57(21):4838-4848
41. Tarceva Package Insert; Genentech Biooncology Inc.
42. Panitumumab Package Insert; Amgen Incorporated
43. Imatinib mesylate package insert; Novartis Pharmaceuticals
44. Samelis GF, Ekmektzoglou KA, Zografos GC (2007) Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy. Eur J Surg Oncol 33(8):942-950
45. Andtbacka RH et al (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14(1):14-24
46. Hasegawa J et al (2007) Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12(3):212-217